First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation

Tanaka, Sébastien; Begue, Floran; Veeren, Bryan; Tran-Dinh, Alexy; Robert, Tiphaine; Tashk, Parvine; Lortat-Jacob, Brice; Faille, Dorothée; de Chaisemartin, Luc; Zappella, Nathalie; Atchade, Enora; Kramer, Laura; Montravers, Philippe; Meilhac, Olivier

doi:10.3390/biomedicines10040754

Open AccessCase Report

First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation

by

Sébastien Tanaka

^1,2,*,†

,

Floran Begue

^2,†,

Bryan Veeren

²,

Alexy Tran-Dinh

^1,3,4,

Tiphaine Robert

⁵,

Parvine Tashk

¹,

Brice Lortat-Jacob

¹,

Dorothée Faille

^3,4,6

,

Luc de Chaisemartin

^7,8,

Nathalie Zappella

¹

,

Enora Atchade

¹,

Laura Kramer

⁹,

Philippe Montravers

^1,3,10

and

Olivier Meilhac

^2,11,*

¹

AP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, France

²

INSERM, UMR 1188 Diabète Athérothombose Réunion Océan Indien (DéTROI), Université de La Réunion, 97400 Saint-Denis, France

³

Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, 75006 Paris, France

⁴

INSERM U1148, Laboratory for Vascular Translational Science, 75018 Paris, France

⁵

AP-HP, Service de Biochimie, CHU Bichat-Claude Bernard, 75018 Paris, France

⁶

AP-HP, Département d’Hématologie Biologique, CHU Bichat-Claude Bernard, 75018 Paris, France

⁷

AP-HP, Département d’Immunologie, CHU Bichat-Claude Bernard, 75018 Paris, France

⁸

Inserm, Inflammation, Microbiome, Immunosurveillance, Université Paris-Saclay, 92290 Châtenay-Malabry, France

⁹

AP-HP, Service de Pharmacie, CHU Bichat-Claude Bernard, 75018 Paris, France

¹⁰

INSERM UMR 1152—PHERE, Physiopathology and Epidemiology of Respiratory Diseases, 75018 Paris, France

¹¹

CHU de La Réunion, CIC-EC 1410, 97400 Saint-Denis, France

Show full affiliation list

Hide full affiliation list

^*

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Biomedicines 2022, 10(4), 754; https://doi.org/10.3390/biomedicines10040754

Submission received: 9 February 2022 / Revised: 14 March 2022 / Accepted: 20 March 2022 / Published: 23 March 2022

(This article belongs to the Special Issue Non-antiviral Agents for Treatment of COVID-19)

Download

Browse Figures

Versions Notes

Abstract

High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections whereas most of the pro-inflammatory proteins identified were less abundant. Assessment of Serum amyloid A-1, inflammatory markers, and cytokines showed a significant decrease for most of them during recombinant HDL infusion. Our results suggest that recombinant HDL infusion is feasible and a potential therapeutic strategy to be explored in COVID-19 patients.

Keywords: COVID-19; lipoprotein; HDL; proteomics; CER-001; case-report; sepsis; cytokines; inflammation

Share and Cite

MDPI and ACS Style

Tanaka, S.; Begue, F.; Veeren, B.; Tran-Dinh, A.; Robert, T.; Tashk, P.; Lortat-Jacob, B.; Faille, D.; de Chaisemartin, L.; Zappella, N.; et al. First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation. Biomedicines 2022, 10, 754. https://doi.org/10.3390/biomedicines10040754

AMA Style

Tanaka S, Begue F, Veeren B, Tran-Dinh A, Robert T, Tashk P, Lortat-Jacob B, Faille D, de Chaisemartin L, Zappella N, et al. First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation. Biomedicines. 2022; 10(4):754. https://doi.org/10.3390/biomedicines10040754

Chicago/Turabian Style

Tanaka, Sébastien, Floran Begue, Bryan Veeren, Alexy Tran-Dinh, Tiphaine Robert, Parvine Tashk, Brice Lortat-Jacob, Dorothée Faille, Luc de Chaisemartin, Nathalie Zappella, and et al. 2022. "First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation" Biomedicines 10, no. 4: 754. https://doi.org/10.3390/biomedicines10040754

APA Style

Tanaka, S., Begue, F., Veeren, B., Tran-Dinh, A., Robert, T., Tashk, P., Lortat-Jacob, B., Faille, D., de Chaisemartin, L., Zappella, N., Atchade, E., Kramer, L., Montravers, P., & Meilhac, O. (2022). First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation. Biomedicines, 10(4), 754. https://doi.org/10.3390/biomedicines10040754

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI